EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

Search

Camurus AB

Gesloten

690.5 1.17

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

672

Max

691.5

Belangrijke statistieken

By Trading Economics

Inkomsten

53M

292M

Verkoop

117M

676M

K/W

Sectorgemiddelde

57.143

37.257

EPS

4.08

Winstmarge

43.235

Werknemers

267

EBITDA

54M

315M

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

189M

41B

Vorige openingsprijs

689.33

Vorige sluitingsprijs

690.5

Camurus AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 okt 2025, 20:45 UTC

Winsten

Costco Wholesale Sales Climb in September, Early October

8 okt 2025, 20:12 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 okt 2025, 16:39 UTC

Belangrijke Marktbewegers

Mining Shares Rise as Gold Prices Soar

8 okt 2025, 23:45 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

8 okt 2025, 23:43 UTC

Marktinformatie

Gold Falls on Possible Profit-Taking -- Market Talk

8 okt 2025, 23:18 UTC

Acquisities, Fusies, Overnames

JD Logistics to Finance Acquisition Using Internal Funds

8 okt 2025, 23:17 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 okt 2025, 23:16 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 okt 2025, 21:54 UTC

Marktinformatie
Winsten

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 okt 2025, 21:30 UTC

Marktinformatie

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 okt 2025, 21:26 UTC

Marktinformatie
Winsten

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 19:15 UTC

Marktinformatie

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 okt 2025, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 okt 2025, 18:47 UTC

Marktinformatie

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Will Remain a Publicly Traded Co >TASK

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 okt 2025, 18:07 UTC

Marktinformatie

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 okt 2025, 15:57 UTC

Marktinformatie

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 okt 2025, 15:56 UTC

Marktinformatie

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 okt 2025, 15:53 UTC

Marktinformatie

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 okt 2025, 15:43 UTC

Acquisities, Fusies, Overnames

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 okt 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer Vergelijking

Prijswijziging

Camurus AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
help-icon Live chat